# US 2013/0156865 A1 · Potentiation induced by pde4 inhibitors in the treatment of leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156865 A1
- Document ID: US20130156865A1
- Status: Published application
- Kind: A1
- Application number: 13/714,938
- Filed: 2012-12-14
- Published: 2013-06-20
- Earliest claimed: 2011-12-16
- Assignees: Chiesi Farmaceutici S.p.A.
- Inventors: Antonio Bonati; Paolo Lunghi
- Web page: https://patentgrep.com/patent/US20130156865A1

## CPC

- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/203: Retinoic acids {; Salts thereof}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 33/36: Arsenic; Compounds thereof
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Certain PDE-4 inhibitors are useful for the treatment of myeloid and linphoyd malignancies.

## Claims

### Claim 1

A combination comprising:
(A) at least one compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
n is 0 or 1;
R1 and R2, which may be the same or different, are independently:
linear or branched (C1-C6)alkyl, optionally substituted by one or more halogen atoms;
OR3, wherein R3 is a linear or branched (C1-C6)alkyl group optionally substituted with one or more halogen atoms or C3-C7 cycloalkyl groups; or
HNSO2R4, wherein R4 is a linear or branched (C1-C4)alkyl group optionally substituted with one or more halogen atoms,
wherein at least one of R1 and R2 is HNSO2R4; and
(B) at least one of:
(i) at least one retinoid and/or
(ii) at least one arsenic derivative.

### Claim 2 (depends on 1)

A combination according to claim 1, wherein said compound of formula (I) is selected from the group consisting of:
(−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-pyridin-4-yl)-ethyl ester;
(−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-4-cyclopropylmethoxy-3-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-3,4-bis-methanesulfonylamino-benzoic acid 1-(3-cyclopropyl-methoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-3-methanesulfonylamino-4-methyl-benzoic acid 1-(3-cyclopropyl-methoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester; and
(−)-4-methanesulfonylamino-3-methyl-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;

### Claim 3 (depends on 2)

A combination according to claim 2, wherein said compound of formula (I) is (−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester.

### Claim 4 (depends on 1)

A combination according to claim 1, wherein said arsenic derivative is selected from the group consisting of arsenic disulfide, arsenic trisulfide, and arsenic trioxide.

### Claim 5 (depends on 4)

A combination according to claim 4, wherein said arsenic derivative is arsenic trioxide (ATO).

### Claim 6 (depends on 5)

A combination according to claim 5, wherein said arsenic trioxide is present in an amount to result in administration of a daily dose of 0.01 to 1.0 mg/kg body weight.

### Claim 7 (depends on 1)

A combination according to claim 1, wherein said retinoid is selected from the group consisting of all-trans retinoic acid, 9-cis retinoic acid, 13-cis retinoic acid, vitamin A (retinol), and carotene.

### Claim 8 (depends on 7)

A combination according to claim 7, wherein said retinoid is all-trans retinoic acid (ATRA).

### Claim 9 (depends on 8)

A combination according to claim 8, wherein all-trans retinoic acid is present in an amount to result in administration of a daily dose of 0.01 to 10 mg/kg body weight.

### Claim 10 (depends on 1)

A combination according to claim 1, wherein said retinoid is all-trans retinoic acid and is present in an amount to result in administration of a daily dose of about 0.4 to 0.6 mg/kg body weight, and said arsenic derivative is arsenic trioxide and is present in an amount to result in administration of a daily dose of about 0.05 to 0.1 mg/kg body weight.

### Claim 11 (depends on 1)

A medicament, comprising a fixed combination of at least one compound of formula (I) as defined in claim 1, and either at least one retinoid and/or at least one arsenic derivative, and optionally a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 1)

A kit comprising;
a) a compound of formula (I) as defined in claim 1, and optionally a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
b) a retinoid and optionally a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and/or
c) an arsenic derivative, and optionally a pharmaceutically acceptable carrier or diluent in a third unit dosage form;
d) container means for containing said first, second and optionally third dosage forms.

### Claim 13

A method for the treatment of a hematological malignancy, comprising administering an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
n is 0 or 1;
R1 and R2, which may be the same or different, are independently:
linear or branched (C1-C6)alkyl, optionally substituted by one or more halogen atoms;
OR3, wherein R3 is a linear or branched (C1-C6)alkyl group optionally substituted with one or more halogen atoms or C3-C7 cycloalkyl groups; or
HNSO2R4, wherein R4 is a linear or branched (C1-C4)alkyl group optionally substituted with one or more halogen atoms,
wherein at least one of R1 and R2 is HNSO2R4;
to a subject in need thereof.

### Claim 14 (depends on 13)

A method according to claim 13, wherein said compound of formula (I) is selected from the group consisting of:
(−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-pyridin-4-yl)-ethyl ester;
(−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-4-cyclopropylmethoxy-3-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-3,4-bis-methanesulfonylamino-benzoic acid 1-(3-cyclopropyl-methoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;
(−)-3-methanesulfonylamino-4-methyl-benzoic acid 1-(3-cyclopropyl-methoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester; and
(−)-4-methanesulfonylamino-3-methyl-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester;

### Claim 15 (depends on 13)

A method according to claim 13, wherein said compound of formula (I) is (−)-3-cyclopropylmethoxy-4-methanesulfonylamino-benzoic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester.

### Claim 16 (depends on 13)

A method according to claim 13, wherein said malignancy is lymphocytic or myeloid leukemia, either acute or chronic.

### Claim 17 (depends on 13)

A method according to claim 13, wherein the myeloid leukemia form is acute promyelocytic leukemia.

### Claim 18 (depends on 13)

A method according to claim 13, further comprising administering at least one retinoid to said subject in need thereof.

### Claim 19 (depends on 13)

A method according to claim 13, further comprising administering at least one arsenic compound to said subject in need thereof.

### Claim 20 (depends on 13)

A method according to claim 13, further comprising administering at least one retinoid and at least one arsenic compound to said subject in need thereof.
